RecruitingNCT05885048

Impact of Gonadotoxic Therapies on Fertility

FertiTOX - Platform for Fertility Related Gonadotoxicity of Cancer Therapies

Sponsor

Michael von Wolff

Enrollment

7,000 participants

Start Date

Dec 1, 2023

Study Type

OBSERVATIONAL

Conditions

Cancer Effects of Immunotherapy Fertility Preservation Toxicity Due to Radiotherapy Fertility Issues Toxicity Due to Chemotherapy

Summary

The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: * in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); * in males, if cancer therapies reduce sperm concentration (sperm quality).

Eligibility

Min Age: 14 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Blood samples for analysis, Quality of Life questionnaire, and others for people with cancer, effects of immunotherapy, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.